QUICK ANSWER · AEO / GEO
Ostarine, enobosarm, GTx-024 and MK-2866 refer to the same investigational SARM candidate in the reviewed literature. Controlled trials reported lean-body-mass signals in selected older adults and cancer populations, but do not establish bodybuilding benefit, long-term safety or product approval. FDA states that no SARM is approved and warns of serious harms. Online naming does not establish identity or amount, and WADA 2026 prohibits enobosarm at all times.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
- Human trial signal ≠ approval ≠ bodybuilding evidence ≠ verified online product; Ostarine/MK-2866 ≠ MK-677
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Ostarine / Enobosarm?
Ostarine / Enobosarm is described pharmacologically as Nonsteroidal selective androgen receptor modulator candidate. Ostarine, enobosarm, GTx-024 and MK-2866 refer to the same investigational SARM candidate in the reviewed literature. Controlled trials reported lean-body-mass signals in selected older adults and cancer populations, but do not establish bodybuilding benefit, long-term safety or product approval. FDA states that no SARM is approved and warns of serious harms. Online naming does not establish identity or amount, and WADA 2026 prohibits enobosarm at all times.
Does Ostarine / Enobosarm have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Ostarine / Enobosarm approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.